Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01908062 · ClinicalTrials.gov registry record · Phase 3
Comparing Treatments for HIV-Infected Opioid and Alcohol Users in an Integrated Care Effectiveness Study
A Phase 3 study, sponsored by Oregon Health and Science University.
- Completed
- Registry status
- Phase 3
- Development phase
- 51
- Enrollment target
NCT01908062: Completed Phase 3 study, sponsored by Oregon Health and Science University.
NCT01908062 is a Phase 3 study that has completed, run by Oregon Health and Science University. The registered enrollment target is 51 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01908062, a Phase 3 study, has completed, sponsored by Oregon Health and Science University.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 51 participants
- Enrollment target
Study Summary
The purpose of this study is to learn how best to treat substance use disorders in an HIV clinic setting. Specifically, the purpose of this pilot study is to learn if extended-release naltrexone (XR-NTX) would be a feasible and acceptable treatment for HIV-infected individuals with opioid or alcohol use disorders.
Primary Outcome
Successful induction onto XR-NTX or initiation of treatment as usual within 4 weeks of randomization.
Interventions
- DRUG Extended Release Naltrexone
- OTHER Treatment As usual
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2014-06 |
| Est. Completion | 2015-03 |
| Phase | Phase 3 |
What the finished NCT01908062 record still lists
NCT01908062 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 51 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (93% lower).
The record links to 0 conditions, and to 2 interventions - of which Extended Release Naltrexone is the first listed.
NCT01908062 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01908062 about?
NCT01908062 is a clinical study titled "Comparing Treatments for HIV-Infected Opioid and Alcohol Users in an Integrated Care Effectiveness Study". The purpose of this study is to learn how best to treat substance use disorders in an HIV clinic setting. Specifically, the purpose of this pilot study is to learn if extended-release naltrexone (XR-NTX) would be a feasible and acceptable treatment for HIV-infected individuals with opioid or alcohol...
What is the current status of trial NCT01908062?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 51 participants. The study started on 2014-06. Estimated completion is 2015-03.
What interventions are being tested in trial NCT01908062?
The interventions under investigation include: Extended Release Naltrexone (DRUG), Treatment As usual (OTHER).
Who is sponsoring clinical trial NCT01908062?
This trial is sponsored by Oregon Health and Science University, which has 546 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01908062's enrollment target sits among peer trials
51 1842nd of 2000 higher than 157 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02701153 · 51 participants · NA
Phase II Study of 5-Day Hypofractionated Preoperative Radiation Therapy for Soft Tissue Sarcomas: Expansion Cohort
- NCT03663790 · 51 participants · NA
Effects of Gait Retraining on Lower Extremity Biomechanics
- NCT03874052 · 51 participants · Phase 1
Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
- NCT04704661 · 51 participants · Phase 1
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia